Details
|
OSI Pharmaceuticals develops, discovers and commercializes Novel Pharmaceutical and high quality products which extend the life or improve the quality of life for diabetes and cancer patients around the world. OSI divides into 2 business teams: (OSI) Prosidian, and (OSI) oncology. OSI Prosidian generates of novel, targeted therapies for the treatment of type two obesities and diabetes. OSI oncology focuses on development of molecular targeted therapies designed to change the paradigm of cancer care.
The company’s drug, Tarceva (erlotinib), is the first medicine developed and discovered by OSI Pharmaceuticals to obtain FDA approval and the only EGFR inhibitor to have demonstrated the ability to improve survival in pancreatic cancer patients and non-small cell lung cancer. OSI markets Tarceva through partnerships with Genentech, inside the Unites States and with Roche around the world. It also collaborates with Pfizer. The biotechnology company is located in Melville, New York.
|
